Skip to content

Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes

A Prospective Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02086019
Acronym
RINCAL
Enrollment
250
Registered
2014-03-13
Start date
2014-05-01
Completion date
2019-12-12
Last updated
2021-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Keywords

Revascularisation, octogenarian,acute coronary syndromes

Brief summary

For octogenarian patients with NSTEMI (non-ST segment elevation myocardial infarction) an invasive-guided strategy will prove superior to a conservative strategy with respect to a combined endpoint of all cause mortality and non-fatal myocardial infarction.

Interventions

crossover to angiogram only if predefined criteria met

PROCEDUREInvasive Arm

angiogram with PCI or CABG revascularisation if appropriate

Sponsors

Medtronic Vascular
CollaboratorINDUSTRY
Brighton and Sussex University Hospitals NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
80 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* AGE\>80 Non-STEMI - characteristic chest pain accompanied by * Typical ischaemic ECG changes * A troponin rise Suitable for conservative or invasive strategy

Exclusion criteria

* Lack of suitability for whatever clinical reason to be randomised eg dementia, co-morbidity * Acute STEMI * Cardiogenic shock * Platelet count =50 x 109/mm3 * Patient life expectancy \< 1 year * Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or stent drug elutant * Recent major GI haemorrhage (within 3 months) * Any previous cerebral bleeding episode * Participation in another investigational drug or device study * Patient unable to give consent * Clinical decision precluding the use of stents

Design outcomes

Primary

MeasureTime frameDescription
Death1 yearThe cause of death will be adjudicated as being due to cardiovascular causes, non cardiovascular causes, or undetermined causes. * Cardiovascular Death includes sudden cardiac death, death due to acute myocardial infarction, death due to heart failure or cardiogenic shock, death due to stroke or death due to other cardiovascular causes * Non-Cardiovascular Death is defined as any death not covered by cardiac death or vascular death. * Undetermined cause of death refers to a death not attributable to one of the above categories of cardiovascular death or to a non-cardiovascular cause. N.B For this trial all deaths with undetermined causes will be included in the cardiovascular category.
non-fatal myocardial infarction1 yearThe ESC/ACC (European Society of Cardiology and the American College of Cardiology) definition of myocardial infarction will be applied, including the special circumstances of same admission myocardial re-infarction, or myocardial infarction peri-PCI.

Secondary

MeasureTime frameDescription
Permanent Stroke1 yearA stroke is a loss of neurological function caused by an ischemic or hemorrhagic event with residual symptoms at least 24 hours after onset or leading to death
Major bleeding1 yearBARC (Bleeding Academic Research Consortium) definition
Deterioration of renal function during hospital admissionDuring index admissionWorsening renal function is an absolute increase in serum creatinine of ≥ 0.3mg/dl (26.5 umol/l) at any time during hospitalization compared to the valve obtained at admission
Hospital readmission for ACS/STEMIAt 3, 6 and 12 months and at 2,3 and 4 yearsESC/ACC definition ACS/STEMI (Acute coronary syndrome/ST-segment elevation myocardial infarction)
Stent thrombosis1 yearARC definition of stent Thrombosis
All cause mortality2,3 and 4 yearCardiac and non cardiac mortality
In-hospital major complicationsAt 3, 6 and 12 months and at 2,3 and 4In hospital major complications defined as death, myocardial infarction, stent thrombosis, target restenosis, repeat target- and non-target vessel-related percutaneous coronary intervention, target lesion revascularization, coronary artery bypass surgery and stroke.
Angina symptoms (3 months; 1yr)3 months and 1 yearCCS (Canadian Cardiovascular Society Classification of angina) grading of angina
Unplanned revascularisation1 yearsShall be deemed to have occurred at follow-up if any coronary vessel requires or undergoes attempted repeat revascularisation with either balloon angioplasty, stenting, or coronary artery bypass grafting.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026